Google
Trusted Resources: News & Events
Latest announcements and gatherings
Partnership to Ensure Supply of LentiGlobin, Potential Gene Therapy
Bluebird Bio extended a partnership with two divisions of Hitachi Chemical for the long-term development and manufacturing of LentiGlobin, its investigational gene therapy for sickle cell disease (SCD), and other potential and approved treatments.
The two subsidiaries — Hitachi Chemical Advanced Therapeutics Solutions (HCATS) and Apceth Biopharma — will be in charge of late-clinical development and manufacturing of LentiGlobin at facilities in Germany (Apceth) and the U.S. (HCATS).
“It is our honor to support bluebird bio in the manufacture of their potentially transformative gene therapies, to the benefit of patients in both the United States and Europe, as the foundation for our collaboration to address this devastating disease,” Robert Preti, PhD, chief strategy officer at Hitachi Chemical Life Science Business Headquarters, said in a press release.
+myBinderRelated Content
-
Webinar Series: Sickle Cell Science: Path to Progress – Bone Marrow Transplants, Other Therapies, and Sickle C...To commemorate Sickle Cell Awareness Mon...
-
Congo Delegation Visits Howard University to Bolster Collaborations on Sickle Cell DiseaseA Republic of Congo delegation of health...
-
Today’s Faces of Sickle Cell Disease: Pat Corley, RNIn 1979, while she was volunteering at a...
-
RARE Drug Development SymposiumThe RARE Drug Development Symposium is a...
-
Walk for Sickle Cell Disease — Greater Boston Sickle Cell Disease AssociationWe take the safety and wellness of each ...
-
Self‐Management Recommendations for Sickle Cell Disease: A Content Analysis of WebsitesThis paper reports on the findings of a ...
-
10th Annual Walk with the Stars – Sickle Cell Disease Association of America, Inc.When: September 16, 2023 Where: Rash Fi...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
SomeBodyToTalkTo connects people affected by rare diseases with trusted resources, supportive communities, and opportunities to share their experiences.